Amarin Corp Plcuk (AMRN) Other Non-Current Assets (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Other Non-Current Assets of $3.9 million for Q2 2026, up 247.93% year-over-year from $1.1 million in Q2 2025, and up 290.99% quarter-over-quarter from $1.0 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Other Non-Current Assets for 17 consecutive years, with $3.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Assets rose 247.93% year-over-year to $3.9 million; the TTM figure through Jun 2026 stood at $3.9 million (up 247.93% YoY), while the FY2025 annual figure was $1.1 million, down 12.04% from the prior year.
- Other Non-Current Assets rose to $3.9 million in Q2 2026 per AMRN's latest filing, from $1.0 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $3.9 million in Q2 2026 and bottomed at $456000.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $1.2 million across 5 years, with a median of $1.2 million in 2024.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets jumped 259.21% — and 2024, when it retreated 19.76%.
- Amarin Corp Plc\Uk's Other Non-Current Assets stood at $458000.0 in 2022, then surged by 196.94% to $1.4 million in 2023, then dropped by 10.81% to $1.2 million in 2024, then dropped by 12.04% to $1.1 million in 2025, then surged by 270.1% to $3.9 million in 2026.
- Business Quant data shows AMRN's Other Non-Current Assets at $3.9 million in Q2 2026, $1.0 million in Q1 2026, and $1.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 12.98 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 4.75 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 9.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.56 Bn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 3.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.95 Mn |
| Mar 31, 2026 | 1.01 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.11 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 1.21 Mn |
| Sep 30, 2024 | 1.25 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 1.36 Mn |
| Sep 30, 2023 | 1.40 Mn |
| Jun 30, 2023 | 1.60 Mn |
| Mar 31, 2023 | 1.64 Mn |
| Dec 31, 2022 | 458,000.00 |
| Sep 30, 2022 | 456,000.00 |
| Jun 30, 2022 | 456,000.00 |
| Mar 31, 2022 | 456,000.00 |
| Dec 31, 2021 | 456,000.00 |
| Sep 30, 2021 | 456,000.00 |